Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Reports Fourth Quarter and 2021 Financial Results and Provides Business Update
- Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones - - SerpinPC registration studies planned to begin in 2H 2022 following
30.03.2022 - – Company strengthens strategic focus on rare disease and immuno-oncology assets and details expected upcoming clinical milestones – – SerpinPC registration studies planned to begin in 2H 2022 following recent FDA meeting; initial focus on .
Investegate announcements from Centessa Pharmaceuticals plc, Centessa Pharmaceuticals Expands Management Team and Adds to Extensive Development Expertise
BOSTON and LONDON, March 07, 2022 (GLOBE NEWSWIRE) Centessa Pharmaceuticals plc (Nasdaq: CNTA) (the "Company"), a clinical-stage company leveraging its innovative asset-centric business model to discover